The acquisition of Tissuemed expands BD’s offerings for surgeons outside the US and across the globe. Credit: BD / PRNewswire.

Becton, Dickinson and Company (BD) has acquired self-adhesive surgical sealant films developer Tissuemed for an undisclosed amount.

Tissuemed’s sealant technology, Tissuepatch, binds to tissues to prevent leaks from surgical incisions and can be used to control internal bleeding.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

With a thin, flexible and transparent composition, the technology helps clinicians to seal sutured or stapled tissues against leakage of air, blood and other fluids, including cerebrospinal fluid (CSF), after surgical procedures.

It is said to be ideally suited for a range of surgical sealant applications.

BD stated that the acquisition of Tissuemed expands its offerings for surgeons outside the US and across the globe.

It also complements the company’s core portfolio by adding Tissuemed’s surgical sealant to its suite of biosurgery products, which are already being used in the operating room.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

BD surgery president Kevin Kelly said: “This advanced sealant serves as a strategic complement to the BD products used in the operating room today, providing us with the opportunity to equip surgeons with a more robust, highly-integrated portfolio of surgical solutions.

“Integrating Tissuepatch into our business aligns with our commitment to continuously innovate in our core portfolio to help support minimally invasive surgeries.”

With significant growth plans for the next five to ten years, the company plans to use its clinical expertise to advance the sealant technology category.

In October, BD partnered with the US Biomedical Advanced Research and Development Authority (BARDA) to develop a range of Covid-19 combination diagnostic tests.

As part of the partnership, BARDA agreed to provide initial funding of $24.7m to BD, which could be extended up to $40.3m.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Awarded for Innovation in Remote Hearing Diagnostics , hearX’s Self Test Kit (STK) delivers clinically validated audiometry via smart devices, enabling remote, scalable hearing assessments in homes, clinics and retail. Learn how hearX is redefining hearing care delivery and reducing costs for providers globally.

Discover the Impact